- Home
- CIGL vs BTAI Comparison
CIGL vs BTAI Comparison
Compare CIGL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- BTAI
- Stock Information
- Founded
- CIGL 1997
- BTAI 2017
- Country
- CIGL Singapore
- BTAI United States
- Employees
- CIGL N/A
- BTAI N/A
- Industry
- CIGL Diversified Commercial Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- BTAI Health Care
- Exchange
- CIGL Nasdaq
- BTAI Nasdaq
- Market Cap
- CIGL 46.7M
- BTAI 52.7M
- IPO Year
- CIGL 2025
- BTAI 2018
- Fundamental
- Price
- CIGL $2.89
- BTAI $2.48
- Analyst Decision
- CIGL
- BTAI Buy
- Analyst Count
- CIGL 0
- BTAI 5
- Target Price
- CIGL N/A
- BTAI $32.80
- AVG Volume (30 Days)
- CIGL 3.2M
- BTAI 1.6M
- Earning Date
- CIGL 09-29-2025
- BTAI 11-13-2025
- Dividend Yield
- CIGL N/A
- BTAI N/A
- EPS Growth
- CIGL N/A
- BTAI N/A
- EPS
- CIGL N/A
- BTAI N/A
- Revenue
- CIGL $11,072,733.00
- BTAI $868,000.00
- Revenue This Year
- CIGL N/A
- BTAI N/A
- Revenue Next Year
- CIGL N/A
- BTAI $614.78
- P/E Ratio
- CIGL N/A
- BTAI N/A
- Revenue Growth
- CIGL 6.32
- BTAI N/A
- 52 Week Low
- CIGL $1.40
- BTAI $1.17
- 52 Week High
- CIGL $31.06
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- BTAI 38.09
- Support Level
- CIGL N/A
- BTAI $2.47
- Resistance Level
- CIGL N/A
- BTAI $2.70
- Average True Range (ATR)
- CIGL 0.00
- BTAI 0.21
- MACD
- CIGL 0.00
- BTAI -0.00
- Stochastic Oscillator
- CIGL 0.00
- BTAI 9.74
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.